Christine Lovly
Faculty Member
Last active: 9/10/2020

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Ichihara E, Lovly CM
Cancer Discov. 2015 5 (7): 694-6

PMID: 26152920 · PMCID: PMC4499857 · DOI:10.1158/2159-8290.CD-15-0616

In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechanisms of drug resistance. The authors provide a new paradigm for using quantitative assessment of the EGFR T790M:activation mutation allele frequency ratio to prognosticate responses to rociletinib and also demonstrate that plasma-based assessments of circulating tumor DNA can be used to monitor drug response and the emergence of drug resistance.

©2015 American Association for Cancer Research.

MeSH Terms (8)

Acrylamides Drug Resistance, Neoplasm ErbB Receptors Humans Lung Neoplasms Protein Kinase Inhibitors Pyrimidines Small Cell Lung Carcinoma

Connections (1)

This publication is referenced by other Labnodes entities: